Get the latest news on Implanet stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on IMPZY performance

Latest Implanet Stock News | OTC:IMPZY | Benzinga

Implanet SA designs produce and sell medical implants and devices used in orthopedic surgery. Its products include prosthetic knees, spinal bracing systems, intersomatic cages, pins, suture threads, screws, and anchors. The company operates in a single segment - the commercialization of orthopedic implants. It derives Majority of its geographical revenue from France.

News

Intraday Update

Markets

Movers

Trading Ideas

ADNT

ADYEY

ADYYF

AFGC

AFTPF

AIQUY

ALLE

ALSK

ALSWF

ANSS

APTO

AQUA

ARES

ASPU

BCOW

BILL

CBRE

CCXI

CDAY

CFDB

CGEN

CGJTF

CGUD

CHDN

CHGCY

CHTR

CLHRF

CLNXF

CLSD

CNNE

CSOC

CTLT

CTPTY

DDOG

DNLMY

DNPLY

DOCU

DOOO

DSNKY

EDRVF

ELVT

ELYGF

FATE

FJTSY

FLXT

GLGDF

GLIBA

GLPI

GLVMF

GPTRF

GRSFF

HIMX

HPTO

HRNNF

IBDSF

IMMFF

IMPZY

INGIY

INVH

ITMR

IVME

JAGR

JJAQF

KRNT

LBRDA

LBRDK

LPKFF

MCRI

Stocks That Hit 52-Week Highs On Monday

Implanet SA

Citigroup analyst Jon Tower maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Buy and lowers the price target from $43 to $39.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Sweetgreen, Lowers Price Target to $39

On Thursday, NovoCure Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) reported a fourth-quarter loss of 61 cents, down from the 45-cent loss reported a year ago, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 34 cents</a>.
Sales increased 21% year over year to $161.27 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44002398/novocure-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-company-update" rel="noreferrer noopener">consensus of $157.81 million</a>.
<ul>
<li>The U.S., Germany, France and Japan contributed $107.2 million, $17.4 million, $15.7 million and $8.5 million in quarterly net revenues, respectively, with other active markets contributing $10.4 million.</li>
<li>Revenue in Greater China from Novocure's partnership with Zai Lab totaled $2.0 million.</li>
<li>Improved approval rates in the U.S. resulted in $8.3 million of increased net revenue from prior period claims during the quarter.</li>
</ul>
Annual sales reached $605 million, an increase of 19% year-over-year, primarily driven by continued launch success in France for Optune Gio, a wearable, portable, FDA-approved device indicated to treat a type of brain cancer in adult patients 22 years of age or older. Gross margin for the quarter was 79%.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42268730/novocures-recently-approved-tumor-treating-electric-fields-shows-promise-in-pancreatic-cancer-patients" rel="noreferrer noopener">NovoCure&#8217;s Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients</a>
As of December 31, 2024, there were 4,126 total active patients on TTFields therapy globally, with 4,077 active Optune Gio patients on therapy.
As of December 31, 2024, 20 active metastatic NSCLC patients and 29 active malignant pleural mesothelioma (MPM) patients were on Optune Lua, a wearable, portable, FDA-approved device used together with PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41353867/fda-approves-novocures-portable-device-producing-tumor-treating-electric-fields-for-previously-tr" rel="noreferrer noopener">or after a platinum-based regimen</a>.
In 2025, Novocure expects gross margins will be impacted by current and future product enhancements, such as the U.S. launch of Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio and the launch of Optune Lua in mNSCLC.
Net revenue growth in 2025 is expected to reflect growth in Optune Gio active patients. As the GBM business reaches maturity, the company expects to continue growing at a low, mid-single-digit rate this year.
Price Action: NVCR stock is down 10% at $19.77 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/44011524/dentsply-sirona-q4-earnings-miss-10-sales-drop-soft-2025-outlook-and-more" target="_blank" rel="noreferrer noopener">Dentsply Sirona Q4: Earnings Miss, 10% Sales Drop, Soft 2025 Outlook And More</a></li>
</ul>
Photo via Shutterstock.

Biotech

Earnings

Equities

Guidance

Health Care

General

NVCR

NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025

<a href="https://www.washingtonpost.com/technology/2025/02/27/tesla-robotaxi-california-elon-musk/" title="https://www.washingtonpost.com/technology/2025/02/27/tesla-robotaxi-california-elon-musk/">https://www.washingtonpost.com/technology/2025/02/27/tesla-robotaxi-california-elon-musk/</a>

Politics

GOOG

GOOGL

LYFT

TSLA

UBER

'Elon Musk's Tesla moves to launch robotaxi service in California'

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/02/2025-02-27_09h55_19.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Formidable Stage Five</h4>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-nvidia-earnings-quantum-computing-breakthrough-nvda-mc-02272025">click here</a> for an enlarged chart of NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of NVDA is being used to illustrate the point.</li>
<li>The chart shows NVDA stock moved up after the release of earnings.</li>
<li>Going into earnings, the whisper numbers for Nvidia were higher than the consensus. Nvidia earnings came inline with the whisper numbers.&nbsp; Stocks move based on the difference between whisper numbers and the reported numbers.&nbsp; Whisper numbers are the numbers analysts privately share with their best clients.&nbsp; Whisper numbers are often different consensus numbers that the same analysts publish for public consumption.</li>
<li>Initially, NVDA stock moved up on the headlines, but then it fell on concern about margins.&nbsp; In the overnight session, dip buyers came in and aggressively bought NVDA stock, running the stock back up.</li>
<li>The chart shows NVDA stock is now in the resistance zone.</li>
<li>The chart shows the move up was not on low volume.</li>
<li>In The Arora Report analysis, Nvidia earnings were excellent and the concern about margins is misplaced.&nbsp; Due to new product introduction, The Arora Report had expected lower margins.&nbsp; The reported margin is inline with our expectations.&nbsp;&nbsp;</li>
<li>In The Arora Report analysis, the most important point from Nvidia's conference call is that Nvidia has an aggressive new product map.  If Nvidia executes this product map, Nvidia will further distance itself from AMD and custom AI chip makers Broadcom Inc (AVGO) and Marvell Technology Inc (MRVL). </li>
<li>As we have shared with you before, the real issue facing NVDA as a stock is that it is in the formidable stage five of the stages of a long trade.&nbsp; Please <a href="https://thearorareport.com/ppp-long-trade-ppp">click here</a> to see the five stages.&nbsp;&nbsp;</li>
<li>As full disclosure, The Arora Report core position in NVDA with an average price of $12.55 was established when NVDA was in stage one.</li>
<li>The biggest losers from Nvidia earnings have been option players.&nbsp; Premiums on options were very expensive going into earnings as options were indicating a 10% move in NVDA stock after earnings. &nbsp; Since Nvidia has had a muted move after earnings, most of those expensive options are now worthless.</li>
<li>GDP is a lagging indicator, but nonetheless important because the market pays attention to it.&nbsp; The Arora Report focuses on leading indicators.&nbsp; Here are the details of the data:
<ul>
<li>Q4 GDP Second Estimate came at 2.3% vs. 2.3% consensus.</li>
<li>GDP Deflator Second Estimate came at 2.4% vs. 2.2% consensus.</li>
</ul>
</li>
<li>Initial jobless claims came at 242K vs. 220K consensus.&nbsp; In The Arora Report analysis, jobless claims are likely to rise further.&nbsp; Jobless claims is a leading indicator and carries heavy weight in the adaptive <a href="https://thearorareport.com/ALLOCATION%2BMODELS.htm">ZYX Asset Allocation Model</a> with inputs in ten categories.&nbsp; At The Arora Report, we are carefully watching the impact of DOGE on unemployment.&nbsp; So far, the data indicates only 614 former federal civilian employees applying for unemployment.&nbsp; However, prudent investors should note that the data has a two week delay.&nbsp;&nbsp;</li>
<li>Durable goods is mixed.&nbsp; Here are the details:
<ul>
<li>Durable goods came at 3.1% vs. 1.8% consensus.</li>
<li>Durable goods ex-transportation came at 0.0% vs. 0.4% consensus.</li>
</ul>
</li>
<li>Personal income, personal spending, and the Fed's favorite inflation gauge PCE will be released tomorrow at 8:30am ET.</li>
<li>After the recent leap in quantum computing by Microsoft Corp (MSFT), Amazon.com, Inc. (AMZN) has had its own breakthrough.  A team at California Institute of Technology has developed a new quantum computing chip Ocelot that can potentially reduce error correction cost by up to 90%. </li>
<li>In quantum computing, whisper numbers were very high compared to the consensus for IONQ Inc (IONQ).  IONQ reported inline with the consensus.  IONQ is also making a CEO transition, in addition to announcing a $500M at-the-market equity offering.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Amazon (AMZN), Nvidia (NVDA), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), and Tesla Inc (TSLA).
In the early trade, money flows are negative in Apple Inc (AAPL).
In the early trade, money flows were positive in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (QQQ), but as of this writing in the premarket, they have turned negative.
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

NVDA

Excellent Nvidia Earnings But Stage Five Pattern Proves Formidable, Quantum Computing Breakthrough

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower as NVIDIA falls after its quarterly earnings report. Additionally, tariff concerns may be weighing on market sentiment.

In the current market session, Syntec Optics Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) price is at $1.47, after a 5.63% increase. However, over the past month, the stock decreased by 40.07%, and in the past year, by 73.61%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1740684627_0.png" alt="Past Year Chart" />

<h3>Comparing Syntec Optics Holdings P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 24.89 in the Electronic Equipment, Instruments &amp; Components industry, Syntec Optics Holdings Inc. has a higher P/E ratio of 834.83. Shareholders might be inclined to think that Syntec Optics Holdings Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1740684627_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

OPTX

A Look Into Syntec Optics Holdings Inc's Price Over Earnings

Citigroup analyst Ronald Josey maintains Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) with a Buy and lowers the price target from $46 to $39.

XMTR

Citigroup Maintains Buy on Xometry, Lowers Price Target to $39

Citigroup analyst Atif Malik maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Buy and raises the price target from $71 to $73.

CSCO

Citigroup Maintains Buy on Cisco Systems, Raises Price Target to $73

J.P. Morgan analyst Matthew R. Boss reiterated a <a target="_blank" href="https://www.benzinga.com/quote/URBN/analyst-ratings" rel="noreferrer noopener">Neutral rating </a>on the shares of Urban Outfitters Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) and raised the price target from $54.00 to $56.00.
URBN reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43989451/urbn-reports-record-q4-sales-and-fy25-profits" rel="noreferrer noopener">adjusted EPS of $1.04 for fourth-quarter</a>, surpassing analysts&#8217; expectations of $0.95. This was driven by a 16.8% year-over-year increase in gross profit, exceeding the 14% anticipated growth, supported by a 5.1% increase in same-store sales, said the analyst.
Additionally, adjusted gross margin expanded by 200 basis points to 32.3%, surpassing the Street&#8217;s estimate of 31.5%. SG&amp;A expenses were 24.6%, in line with the Street&#8217;s expectation of 24.7%.
Looking forward, management provided guidance for first-quarter 2025, expecting consolidated sales growth of MSD-HSD% year-over-year versus the Street&#8217;s 7.7% forecast.
Same-store sales are anticipated to rise by LSD-MSD%, compared to the Street&#8217;s estimate of 3.4%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/44005238/norwegian-cruise-line-sails-past-q4-expectations-eps-soars-margins-expand-and-demand-stays-hot" rel="noreferrer noopener">Norwegian Cruise Line Sails Past Q4 Expectations: EPS Soars, Margins Expand And Demand Stays Hot</a>
The analyst noted that CEO Hayne clarified that any post-Holiday slowdown in consumer demand was due to &#8220;delayed demand&#8221; caused by weather, with warmer weather markets outperforming northern ones on a comp basis.
The Southeast is the best-performing region, with comps significantly ahead of other areas. Consumer sentiment remains positive and consistent, suggesting potential for delayed demand in northern regions as weather improves, potentially boosting results in March/April.
CEO Hayne&#8217;s remarks about Spring demand and weather align with TJX Companies Inc CEO Herrman&#8217;s, who noted that normal weather areas performed well, but weather disruptions impacted some regions.
The analyst&#8217;s analysis of Chase credit/debit card data indicates that weather has caused a temporary dip in discretionary spending, especially in northern regions where temperatures are significantly colder than last year.
In contrast, states without weather disruptions, like the Southwest, have seen stable.
The analyst raised FY25 EPS estimate to $4.88 (vs. Street $4.42) and FY26 EPS estimate to $5.59 (vs. Street $4.84).
The price forecast is based on 5.6x the analyst&#8217;s FY26 EBITDA (= URBN&#8217;s 3-yr pre-pandemic average), with the linear regression analysis supporting upside to a $68 equity value.
Price Action: URBN shares are trading higher by 9.02% at $57.70 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44001522/beyond-meat-slashes-jobs-and-suspends-china-operations-amid-mixed-q4-results-stock-falls" target="_blank" rel="noreferrer noopener">Beyond Meat Slashes Jobs And Suspends China Operations Amid Mixed Q4 Results; Stock Falls</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Reiteration

URBN

Urban Outfitters Tops Q4 Estimates, But Analyst Stays Neutral Amid Weather-Driven Demand Shifts

Geo Group shares are trading higher after the company reported better-than-expected Q4 sales results and announced it was awarded a 15-year contract by the US Immigration and Customers Enforcement for a facility in New Jersey. Also, a post on X suggested ICE expanded its detention network and all of the beds will be at privately-run ICE jails under deals with the company.

Citigroup analyst David Lebovitz maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $378 to $469.

MDGL

Citigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $469

Citigroup analyst Paul Lejuez maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Neutral and lowers the price target from $38 to $35.

SHOO

Citigroup Maintains Neutral on Steven Madden, Lowers Price Target to $35

Citigroup analyst Tyler Radke maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and lowers the price target from $361 to $339.

ADSK

Citigroup Maintains Buy on Autodesk, Lowers Price Target to $339

Citigroup analyst Asiya Merchant maintains Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) with a Buy and lowers the price target from $80 to $77.

PSTG

Citigroup Maintains Buy on Pure Storage, Lowers Price Target to $77

Citigroup analyst Steven Zaccone maintains Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Neutral and lowers the price target from $47 to $40.

Citigroup Maintains Neutral on Advance Auto Parts, Lowers Price Target to $40

Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares are trading lower by 4.27% to $90.85 during Thursday's session, reversing lower following earlier strength, following Nvidia's <a href="https://www.benzinga.com/news/earnings/25/02/43991607/nvidia-q4-earnings-highlights-revenue-beat-eps-beat-demand-for-blackwell-is-amazing">strong earnings report</a>.
What To Know: While Nvidia's record-breaking fourth-quarter results underscored surging demand for AI infrastructure, they also reinforced its dominance in AI computing, causing investors to reassess expectations for other semiconductor firms like Marvell.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/02/44015237/pending-home-sales-crash-to-record-low-jobless-claims-soar-wall-street-reacts">Pending Home Sales Crash To Record Low, Jobless Claims Soar: Wall Street Reacts</a>
Marvell plays a crucial role in <a href="https://www.benzinga.com/topic/artificial-intelligence">AI infrastructure</a> by providing high-speed networking, custom silicon and data processing solutions for hyperscalers and enterprises. 
The company has been expanding its presence in AI through acquisitions and partnerships, including its investment in custom ASICs, which serve as an alternative to Nvidia's GPUs for certain AI workloads. Its <a href="https://www.benzinga.com/tech/25/02/43611591/behind-marvell-techs-multi-fold-growth-rd-acquisitions-and-ai-infrastructure">acquisition of Innovium</a> also bolstered its high-speed Ethernet switching capabilities, critical for AI-driven data centers.
What Else: Despite Nvidia's continued market leadership, Marvell could remain positioned to benefit from the expanding AI ecosystem. The rapid growth of AI workloads requires advanced networking and compute solutions, areas where Marvell has a strong presence. 
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/02/44018084/trumps-tariffs-potential-stagflation-whats-driving-markets-thursday">Trump&#8217;s Tariffs, Potential &#8216;Stagflation&#8217;: What&#8217;s Driving Markets Thursday?</a>
Investors can gain exposure to&nbsp;MRVL by&nbsp;investing&nbsp;in the&nbsp;VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>).
<h2 class="wp-block-heading">How To Buy MRVL Stock</h2>
By now you're likely curious about how to participate in the market for Marvell Technology &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Marvell Technology, which is trading at $92.38 as of publishing time, $100 would buy you 1.08 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MRVL has a 52-week high of $127.48 and a 52-week low of $53.19.

MRVL

What's Going On With Marvell Technology (MRVL) Stock?

Buybacks

WABC

Westamerica Bancorporation Announces Plans To Repurchase ~7.5% Of Outstanding Shares

TD Securities analyst Craig Hutchison maintains Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) with a Buy and raises the price target from $25 to $28.

PAAS

TD Securities Maintains Buy on Pan American Silver, Raises Price Target to $28

On Thursday, Aurinia Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUPH#NASDAQ">AUPH</a>) reported fourth-quarter earnings of 1 cent per share, compared to a loss of 19 cents a year ago and the consensus loss of 2 cents.
The biopharma company reported fourth-quarter sales of $59.9 million, up 33% year over year, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44000822/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-twelve-months-ended-december-3" rel="noreferrer noopener">consensus of $59.9 million</a>.
<ul>
<li>Net product sales of LUPKYNIS, the first FDA-approved oral therapy for active lupus nephritis, were $57.6 million, up 36%.</li>
<li>License, collaboration, and royalty revenue, which includes manufacturing services revenue and royalties from Aurinia's collaboration partner, Otsuka, was $2.3 million, down 18%.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/44013241/taiwan-semiconductor-faces-government-scrutiny-on-overseas-ventures-amid-intel-stake-rumors" rel="noreferrer noopener">Taiwan Semiconductor Faces Government Scrutiny on Overseas Ventures Amid Intel Stake Rumors</a>
For 2024, net product sales were $216.2 million, up 36%, within the management guidance of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41800433/aurinia-pharmaceuticals-reports-third-quarter-and-nine-months-2024-financial-and-operational-resul" rel="noreferrer noopener">$210 million-$220&nbsp;million</a>.
The company reported an operating loss of $1.67 million compared to $29.7 million a year ago.
Aurinia reported a net income of $1.43 million, better than the loss of $26.9 million.
Aurinia CEO Peter Greenleaf expects 2025 to be &#8220;an exciting year&#8221; for the company when it comes to increasing LUPKYNIS's adoption. Plans are also in place to advance AUR200, which has the potential to treat &#8220;a wide range of autoimmune diseases,&#8221; he adds.
Guidance: Aurinia expects fiscal year revenue of $250 million-$260 million versus the consensus of $274.4 million.
Price Action: Aurinia stock is down 6.35% at $7.45 at the last Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/44008524/hilton-grand-vacations-q4-misses-eps-estimates-boosts-share-repurchase" target="_blank" rel="noreferrer noopener">Hilton Grand Vacations Q4 Misses EPS Estimates, Boosts Share Repurchase</a></li>
</ul>
Image: Shutterstock

AUPH

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) shares are trading lower on Thursday following fourth-quarter results and soft first-quarter <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43992431/ebay-shares-slide-after-q4-results-soft-q1-revenue-guidance" rel="noreferrer noopener">revenue guidance reported on Wednesday</a>.
The company reported earnings per share of&nbsp;$1.25, which beat the analyst consensus estimate of&nbsp;$1.20, and revenue of&nbsp;$2.579 billion marginally exceeded the analyst <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimate of&nbsp;$2.571 billion</a>.
The company sees first-quarter adjusted EPS of $1.32-$1.36, versus the $1.33 estimate, and revenue of $2.52 billion-$2.56 billion, versus the $2.59 billion estimate.
Needham analyst Bernie McTernan reiterated a Buy rating and a price target of $72.
The analyst writes that fourth-quarter results slightly exceeded his expectations. Guidance for 2025 led to minor downward adjustments to his estimates.
eBay continues to outperform other marketplace peers in the coverage, marking its third consecutive quarter of positive gross merchandise value (GMV) growth despite a challenging macroeconomic environment, especially in the U.K. and Germany, adds the analyst.
The analyst now expects GMV growth to remain flat in 2025 vs. previous projection of modest growth owing to a greater foreign exchange headwind.
McTernan says that eBay's core business remains strong, with focus categories growing 6% year-over-year in the fourth quarter, reinforcing the company's path toward sustainable and profitable growth.
As a result, the analyst lowered 2025 estimates for revenue, GMV, and adjusted EBITDA by 0.3%, 1.6%, and 2.4%, respectively, reflecting broader macroeconomic uncertainty, potential tariff impacts, and short-term revenue pressure from the U.K. C2C initiative.
Several analysts revised the price forecast on the stock:
<ul>
<li>Benchmark analyst Daniel Kurnos maintained a Buy rating and raised the price forecast from $65 to $75.</li>
<li>Stifel analyst Mark Kelley kept the Hold rating and lowered the price forecast from $64 to $63.</li>
<li>Barclays analyst Ross Sandler retained an Overweight rating and boosted the price forecast from $64 to $72.</li>
<li>B of A Securities analyst Justin Post reiterated a Neutral rating and slashed the price forecast from $72 to $71.</li>
<li>Wells Fargo analyst Ken Gawrelski maintained an Equal-Weight and raised the price forecast from $61 to $64.</li>
<li>JP Morgan analyst Doug Anmuth retained a Neutral rating and raised the price forecast from $58 to $60.</li>
</ul>
Investors can gain exposure to the stock via&nbsp;ProShares Online Retail ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONLN#NYSE">ONLN</a>) and&nbsp;Global X E-commerce ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBIZ#NASDAQ">EBIZ</a>).
Price Action: EBAY shares are down 6.36% at $64.75 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/02/43492631/dc-luxury-market-responds-to-trumps-return-with-buying-frenzy-as-business-elite-aim-to-infiltrate-inner-circle" target="_blank" rel="noreferrer noopener">DC Luxury Market Responds To Trump&#8217;s Return With Buying Frenzy As Business Elite Aim To Infiltrate Inner Circle</a></li>
</ul>
Image via Shutterstock.

Large Cap

EBAY

EBIZ

ONLN

eBay's Growth Story Intact? Analyst Sees Strength But Warns Of Tariff And FX Challenges

Implanet

Comments

Implanet Stock News

News

Latest Implanet Stock News | OTC:IMPZY | Benzinga

Monday, February 03, 2020

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga